Sino Biopharmaceutical Statistics
Share Statistics
Sino Biopharmaceutical has 894.68M
shares outstanding. The number of shares has increased by 1.42%
in one year.
| Shares Outstanding | 894.68M |
| Shares Change (YoY) | 1.42% |
| Shares Change (QoQ) | 1.42% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 14 |
| FTD / Avg. Volume | 17.95% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is 29.02 and the forward
PE ratio is null.
Sino Biopharmaceutical's PEG ratio is
1.09.
| PE Ratio | 29.02 |
| Forward PE | n/a |
| PS Ratio | 3.52 |
| Forward PS | n/a |
| PB Ratio | 3.18 |
| P/FCF Ratio | 0 |
| PEG Ratio | 1.09 |
Financial Ratio HistoryEnterprise Valuation
Sino Biopharmaceutical has an Enterprise Value (EV) of 2,031.4B.
| EV / Sales | 70.37 |
| EV / EBITDA | 332.54 |
| EV / EBIT | 0 |
| EV / FCF | 0 |
Financial Position
The company has a current ratio of 1.26,
with a Debt / Equity ratio of 0.31.
| Current Ratio | 1.26 |
| Quick Ratio | 1.14 |
| Debt / Equity | 0.31 |
| Debt / EBITDA | 1.6 |
| Debt / FCF | n/a |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is 10.95% and Return on Invested Capital is 10.63%.
| Return on Equity | 10.95% |
| Return on Assets | 5.35% |
| Return on Invested Capital | 10.63% |
| Revenue Per Employee | $1,184,058.37 |
| Profits Per Employee | $143,559.37 |
| Employee Count | 24,379 |
| Asset Turnover | 0.44 |
| Inventory Turnover | 2.25 |
Taxes
| Income Tax | 492.92M |
| Effective Tax Rate | 9.34% |
Stock Price Statistics
The stock price has increased by 31.67% in the
last 52 weeks. The beta is 0.73, so Sino Biopharmaceutical's
price volatility has been higher than the market average.
| Beta | 0.73 |
| 52-Week Price Change | 31.67% |
| 50-Day Moving Average | 8.84 |
| 200-Day Moving Average | 8.31 |
| Relative Strength Index (RSI) | 64.18 |
| Average Volume (20 Days) | 78 |
Income Statement
In the last 12 months, Sino Biopharmaceutical had revenue of 28.87B
and earned 3.5B
in profits. Earnings per share was 2.
| Revenue | 28.87B |
| Gross Profit | 23.53B |
| Operating Income | 6.28B |
| Net Income | 3.5B |
| EBITDA | 6.11B |
| EBIT | 5.17B |
| Earnings Per Share (EPS) | 2 |
Full Income StatementBalance Sheet
The company has 9.57B in cash and 9.78B in
debt, giving a net cash position of -214.26M.
| Cash & Cash Equivalents | 9.57B |
| Total Debt | 9.78B |
| Net Cash | -214.26M |
| Retained Earnings | n/a |
| Total Assets | 65.41B |
| Working Capital | 5.13B |
Full Balance SheetMargins
Gross margin is 81.51%, with operating and profit margins of 21.76% and 12.12%.
| Gross Margin | 81.51% |
| Operating Margin | 21.76% |
| Pretax Margin | 18.28% |
| Profit Margin | 12.12% |
| EBITDA Margin | 21.16% |
| EBIT Margin | 21.76% |
| FCF Margin | n/a |
